THEMISMED
Themis Medicare Limited
Each stock's 10,000-path forecast, rendered as light.
Themis Medicare Limited (THEMISMED) Stock Analysis & Case Study
Is THEMISMED a good buy? The data-driven verdict.
Themis Medicare Limited (THEMISMED) trades at ₹113,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 28/100.
On the numbers, Themis Medicare Limited (THEMISMED) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 632.0× earnings, ROE of 0.4%, a 48% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
THEMISMED fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How THEMISMED ranks against the 2,373 companies in our screener
- THEMISMED's market cap of 1,018 Cr ranks in the 39th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THEMISMED's book value of ₹43 ranks in the 30th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THEMISMED's promoter holding of 67.1% ranks in the 67th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THEMISMED's 3-year profit (PAT) growth of -69.0% ranks in the bottom 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THEMISMED's 3-year revenue growth of -1.0% ranks in the 22nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THEMISMED's debt-to-equity ratio of 0.25x is lower than 57% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is THEMISMED overvalued? THEMISMED P/E vs peers
THEMISMED trades at 632.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
THEMISMED share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of THEMISMED history (8%/yr drift, 56%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| THEMISMED 2027 | ₹53 | ₹108 | ₹221 | -2% |
| THEMISMED 2028 | ₹38 | ₹106 | ₹295 | -4% |
| THEMISMED 2029 | ₹30 | ₹103 | ₹357 | -6% |
| THEMISMED 2030 | ₹25 | ₹101 | ₹417 | -8% |
| THEMISMED 2031 | ₹20 | ₹99 | ₹490 | -10% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability THEMISMED goes up, or doubles?
The bull case for THEMISMED
- Themis Medicare Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹357.
The bear case & risks
- THEMISMED's P/E of 617.0x is lower than 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THEMISMED's return on equity of 0.4% ranks in the 13th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (56%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹30.
THEMISMED volatility & expected range, how bumpy is the ride?
Over the last 9.8 years THEMISMED compounded at 8%/year with annualized volatility of 56%. That volatility implies a 1-year 80% range of ₹53-₹221, the honest backbone behind any single price target.
THEMISMED price forecast, the full 60-month probability fan
THEMISMED price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds THEMISMED hits common targets within the simulated horizon?
Full multi-horizon detail on the THEMISMED price target & forecast page.
THEMISMED Piotroski F-Score: 4/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. THEMISMED scores 4/8, mixed financial health.
THEMISMED MTF margin & leverage across 5 brokers
Margin Trading Facility lets you buy THEMISMED with part of the capital. Lower margin % = higher leverage. Rates compared across 5 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Zerodha | 50.00% | 2.0× |
| Kotak Neo | 100.00% | 1.0× |
| Pocketful | 50.00% | 2.0× |
| Anand Rathi | 40.43% | 2.5× |
| Share IndiaCHEAPEST | 40.31% | 2.5× |
Compare every broker on the THEMISMED MTF page.
About Themis Medicare Limited: sector, index & market-cap context
Themis Medicare Limited (THEMISMED) is a small-cap NSE-listed company, with a market capitalisation of ₹1,043 Cr. See more stocks on our screener.
How the THEMISMED Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Themis Medicare Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
THEMISMED analysis, FAQs
Is Themis Medicare Limited (THEMISMED) a good buy?
On the numbers, Themis Medicare Limited (THEMISMED) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 632.0× earnings, ROE of 0.4%, a 48% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is THEMISMED overvalued or undervalued?
THEMISMED trades at 632.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the THEMISMED share price target for 2031?
THEMISMED's probability-weighted 2031 median target is ₹99, with an 80% range of ₹20-₹490 (10,000-path Monte-Carlo).
What is the probability THEMISMED doubles in 5 years?
The modelled probability of THEMISMED reaching ₹221 (2×) within 5 years is 26%.
What is the bull case for THEMISMED?
Themis Medicare Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in THEMISMED?
THEMISMED's P/E of 617.0x is lower than 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. THEMISMED's return on equity of 0.4% ranks in the 13th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (56%/yr) means a wide, bumpy range of outcomes, size positions accordingly.